Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “It is a prodrug that uses Doxorubicin to target KRAS mutant/ PTEN loss advanced cancer.”In the company’s words, NCT06944457 on ClinicalTrials.gov
- Tested for
- Cancer, Solid Tumor Cancer, Biomarkers
- Main trialPhase 1
- “A Phase I, Open-label, Single-center, Dose-escalation and Dose-finding Clinical trial to evaluate the safety, tolerability and pharmacokinetics of MPD-1 in patients with advanced solid tumor”In the company’s words, NCT06944457 on ClinicalTrials.gov
Other drugs for Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up1
- 31 DecPhase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 31 Dec 2026 | Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of MPD-1 in Patients With Advanced Solid Tumor |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026